• Alias: ABT-263
    • An orally potent and highly selective inhibitor of antiapoptotic members of the BCL-2 family, with a nanomolar affinity for BCL-2, BCL-xL, and BCL-w
    • Currently in phase 1/2 clinical trials for SCLC neuroendocrine cancers, metastatic melanoma, and CLL; leukemia; phase 2 trial in resistant/refractory ovarian cancer
    • Recommended phase 2 dose: Up to 250 mg PO daily on a 21-day cycle
    • Half-life: â™15 hours
    • Side effects: Nausea/vomiting/diarrhea, fatigue/dizziness, thrombocytopenia, neutropenia, pyrexia, increased ALT
    (Gandhi et al., 2011)
    Other topics in Targeted and Immunotherapy Agents